KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $1.2 million.

  • Co-Diagnostics' Accumulated Expenses fell 3403.81% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 3403.81%. This contributed to the annual value of $2.6 million for FY2024, which is 1791.15% up from last year.
  • Per Co-Diagnostics' latest filing, its Accumulated Expenses stood at $1.2 million for Q3 2025, which was down 3403.81% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' Accumulated Expenses registered a high of $4.0 million during Q2 2021, and its lowest value of $934447.0 during Q4 2022.
  • For the 5-year period, Co-Diagnostics' Accumulated Expenses averaged around $1.9 million, with its median value being $1.6 million (2023).
  • As far as peak fluctuations go, Co-Diagnostics' Accumulated Expenses surged by 47875.79% in 2021, and later tumbled by 7578.93% in 2022.
  • Quarter analysis of 5 years shows Co-Diagnostics' Accumulated Expenses stood at $3.9 million in 2021, then tumbled by 75.79% to $934447.0 in 2022, then skyrocketed by 132.54% to $2.2 million in 2023, then rose by 17.91% to $2.6 million in 2024, then plummeted by 52.98% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.0 million for Q2 2025, and $1.6 million during Q1 2025.